Page 1 of 2

PITC PHARMA, INC. MONITORING REPORT OF PERFORMANCE TARGETS 3RD QUARTER OF 2015

CUSTOMERS						FINA	NCI	AL		A STATEMENT OF THE PROPERTY OF		erspective				
Sub-tot	SM 7	S0 5	9 WS	SO 4	Sub-tot	SW 5	SO 3	SM 4	SO 2	Sub-tot	SM 3	SM 2	SM 1	SO 1		
Sub-total of Weights	Number of suppliers participating in procurement activities for trade goods	Ensure a Transparent and Fair Business Process for	SM 6 Overall satisfaction rating	Achieve Customer Satisfaction	Sub-total of Weights	Sustain the Organization's Viability SM 5 Positive EBITDA		SM 4 Amount of Sales net of VAT	Grow Sales	Sub-total of Weights	Number of Local Government Units (LGUs) served by PPI SM 3 Provinces - 80; Cities - 122 and Municipalities - 1,496	Number of PHIC-Contracted and DOH Medicines Access Sites SM 2 served/Total Number of PHIC-Contracted and DOH Medicines Access Sites	Participate in all DOH, PHIC and PCSO bidding. Present price list, price of winning bidder should be comparable or lower than the price offered by PPI for oncology and vaccines.	Provide Access to Affordable Essential Medicines through	Objective/Measure	Component
	Actual/Target x Weight	Actual/Target x Weight Isiness Process for Actual/Target x		Actual/Tarnaty		Actual/Target x Weight	Actual/Target x Weight				Actual/Target x Weight	Actual/Target x Weight	Actual/Target x Weight	sential Medicines	Rating Scale	
10%	5%	or	5%		30%	10%		20%		35%	10%	10%	15%		Weight	
	25		Above Satisfactory			Php 17.62 million	THE PROPERTY OF THE PROPERTY O	Php 541.96 million			950	22 out of 25	NA		2014	Baseline
					NAME OF THE PARTY	Php 7.322 million	Antonio contigente de la consequencia della consequencia della consequencia della consequencia della della consequencia della consequencia della consequencia della c	Php 181.290 million			900	72% (18 out of 25)	90%		Target	1st Quarter
	45					Php (4.186 million)		Php 53.91 million	Albacon, electric company and the property of		1,615	100% (25 out of 25)	100%		Actual	arter
	24					Php 25.394 Php million million)	Php 522.239 million			1,000	87% (21 out of 25)	90%		Target	2nd Quarter	
	85						Php 179.820 million			1,615	100% (25 out of 25)	100%		Actual	ırter	
															Revised Full Year Target	2015
	31					Php 35.881 million		Php 762.294 million			1,050	88% (22 out of 25)	90%		Target	3rd Quarter
	95					Php 2.475 million		Php 533.629 million			1,615	100% (25 out of 25)	100%		Actual	ırter
	38		Above Satisfactor y			Php 36 million		Php 900.006 million			1,104	100% (25 out of 25)	90%		Target	4th Quarter
					annian consultanticular										Actual	arter
	Done					Request for decrease in EBITDA target from P36 M to P4.807M due to the input VAT charged to expense discussed during the TWG meeting.	(XXXIII O)	Anti TB Drugs for Children worth P30 M and Sphygmomanometer worth P160.072M for delivery in the 4th Ouerter			Done	Done	No bidding conducted for Oncology. For Vaccines, there is no local supplier who can meet the big volume requirement of DOH and DOH usually purchase from Unicef.		Remarks	

Page 2 of 2

PITC PHARMA, INC. MONITORING REPORT OF PERFORMANCE TARGETS 3RD QUARTER OF 2015

			TH AN		EARNING			INT	Perspective							
Accumul	P101-CINC	SM 12		SO 8 SM 11			SM 10	_	807	e MS	8 MS		80 G			
Accumulated Total Weight	Sup-total of Areigns	SM 12 ISO Certification	SO Certification		SM 11 Units achieving its target	Develop Organizational Competencies	Sub-total of Weights	DOH, PHIC and PCSO	% of orders delivered on time for	Deliver Responsive and Timely Services to Customers	SM 9 New business partnerships		New product lines and packages introduced	Expand Product Lines and Business Partnerships	Objective/Measure	Component
		All or nothing		Institutionalize a Quality Management System	Actual/Target x Weight but not less than	icies		Actua/Target x Weight		ervices to Custom	Actual/Target x Weight	Actual/Target x Weight		ess Partnerships	Rating Scale	
100%	10%		5%		5%		5%				Weight					
		and Documentatio n Training	Completion of		NA		Ventabilingsagataling in Antiquesemprepries	85%			2	2			2014	Baseline
	A Communication of the communi				-			90%					-		Target	1st Quarter
Period Production payments and a payment between the payment of th								75%			1 (Bio Pharma)	1 - Anti TB		Actual	ıarter	
						-	AND THE PROPERTY OF THE PROPER	90%							Target	2nd Quarter
								75%			1 (Bio Pharma)	1 - Anti TB			Actual	rter
															Revised Full Year Target	2015
								90%							Target	3rd Quarter
			ISO					86%				2- Sphygmo nameter 3- Insulin	1- Anti TB		Actual	rter
		Certification n all sites all processes			Oi	Oi		90%			ω	ω			Target	4th Quarter
															Actual	arter
		To be Certified within the year					Philhealth- 2 Sales Orders - on time; PCSO- 2 Sales Orders - on time; DOH- 3 Projects- 2 on time, 1 delayed.			PhilHealth and Abbott Philippines	Done			Remarks		